Subset of patients with lung cancer have poor response to COVID-19 vaccines

Most patients with non-small cell lung cancer had an adequate antibody response to COVID-19 vaccines, research published in Journal of Clinical Oncology showed.
However, up to a quarter of patients had a poor response to vaccines, including low neutralizing antibodies to the B.1.1.529 omicron variant. Poor responders showed increased neutralizing antibodies to omicron variants that declined precipitously 3 months after booster doses, highlighting a high-risk population in need of optimized vaccination strategies, the researchers noted.
Patients with lung cancer are “among those at

Most patients with non-small cell lung cancer had an adequate antibody response to COVID-19 vaccines, research published in Journal of Clinical Oncology showed.
However, up to a quarter of patients had a poor response to vaccines, including low neutralizing antibodies to the B.1.1.529 omicron variant. Poor responders showed increased neutralizing antibodies to omicron variants that declined precipitously 3 months after booster doses, highlighting a high-risk population in need of optimized vaccination strategies, the researchers noted.
Patients with lung cancer are “among those at